Peter Nash

POS0773 (2025) LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: LONG-TERM RESULTS FROM PHASE 2B/3 TRIALS - 5000 pt yrs AxSpA & PsA - low uveitis rates - bime or selection? #bimekizumab #uveitis #AxSpA #PsA

POS0109 (2025) COMPARATIVE PERSISTENCE AND EFFECTIVENESS OF IXEKIZUMAB VERSUS OTHER b/tsDMARD CLASSES IN REAL-WORLD PsA TREATMENT: 12-MONTH RESULTS FROM THE PRO-SPIRIT STUDY - a practical comparison #ixekizumab #TNF #IL23i

OP0096 (2025) Sonelokimab, IL-17A- & IL-17F- Nanobody, outcomes PsA: Ph 2 ARGO trial SLK 60mg n=41 SLK 120mg n=43 ADA ref n=42 MDA(n/%) 25 (61.0). 22 (51.2). 19 (45.2) nanobody effective- question is same or better? #IL17 #nanobody #sonelokimab

OP0091 (2025) MARKERS OF IL-17 SIGNALLING IN THE BLOOD OF PATIENTS WITH PSORIATIC ARTHRITIS WITH INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS interesting - 17F raised in TNF non-responders PsA - #IL17F #PsA #TNF-IR

12 mths AbA delays RA up to 3 yrs esp if high titre ACPA

Hence the Emery editorial in Rheumatology journal - biosimilar Toci from day 1 #RA #Tocilizumab #MTX

stratify for gender baseline clinical trials jrheum.org/content/early/…

no excuses jrheum.org/content/early/…

Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ... medpagetoday.com/endocrinology/… need the best for IMIDs

BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection | New England Journal of Medicine nejm.org/doi/full/10.10… Doesnt protect.

Varenna, M., Zucchi, F., Di Taranto, R. et al. Osteoclast in CRPS: an alleged guilty fully acquitted. Osteoporos Int 36, 737–740 (2025). doi.org/10.1007/s00198… its not the Osteoclast! but perhaps dependent on acute vs chronic changes

From DNA to PGA David Pisetsky, MD, PhD May 07, 2025 📷 Investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978..MTP session on the Type 1 & 2 model for SLE - relevant for CAR-T & D2T vs C2M in SLE as well as RA PsA AxSpA #RheumNow # SLE #D2T

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | New England Journal of Medicine nejm.org/doi/full/10.10… FDA approved now #GCA #Upadcitinib

A new toxicity syndrome in patients with autoimmune disease treated with CAR T-cell therapy - The Lancet Rheumatology thelancet.com/journals/lanrh… We need comparative studies! #CAR-T #LICATS

i have been using once a month risedronate post denosumab cessation - here zoledronate useful alternative #citeas" target="_blank" rel="nofollow noopener">link.springer.com/article/10.100…

worth considering for our joint replacement patients link.springer.com/article/10.100…

Human Papillomavirus Vaccination and Actinic Keratosis Burden jamanetwork.com/journals/jamad… affects many of our patients MTX, TNFs, JAKs + QLD sun ! #IMID #HPVvax #RheumNow

@MithuRheum @RheumOnePagers @Lupus_Chat @LupusResearch @LupusInitiative @CaringForLupus @LADAOrg @CreakyJoints needs head to head against full dose rituximab not placebo

🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial Phase 3 RCT: Obi vs PBO 🫘 Pts w/ SLE nephritis Class III/IV ± 5 🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids) 📊 Obi: ⇡rate of renal response #LupusNephritis #RheumTwitter #NephTwitter #Lupus

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine nejm.org/doi/full/10.10… not seen in IMID CAR-T cell therapy yet but instructive nevertheless

worth a read # long covid acrjournals.onlinelibrary.wiley.com/doi/full/10.10…